Assembly Biosciences (NASDAQ:ASMB) Stock Rating Lowered by StockNews.com

StockNews.com lowered shares of Assembly Biosciences (NASDAQ:ASMB - Free Report) from a buy rating to a hold rating in a research note published on Monday.

Separately, HC Wainwright reiterated a "neutral" rating on shares of Assembly Biosciences in a report on Monday.

Assembly Biosciences Stock Performance

Shares of ASMB stock traded down $0.03 on Monday, hitting $10.87. 1,947 shares of the stock traded hands, compared to its average volume of 24,866. Assembly Biosciences has a twelve month low of $10.27 and a twelve month high of $19.93. The firm's 50-day moving average price is $12.63 and its two-hundred day moving average price is $14.99. The stock has a market capitalization of $81.56 million, a PE ratio of -1.62 and a beta of 0.62.

Assembly Biosciences (NASDAQ:ASMB - Get Free Report) last posted its quarterly earnings results on Thursday, March 20th. The biopharmaceutical company reported ($1.57) earnings per share for the quarter, beating the consensus estimate of ($1.75) by $0.18. The business had revenue of $7.36 million during the quarter, compared to analysts' expectations of $7.05 million. Assembly Biosciences had a negative net margin of 144.05% and a negative return on equity of 121.46%. On average, equities research analysts anticipate that Assembly Biosciences will post -6.87 EPS for the current fiscal year.

Insider Buying and Selling at Assembly Biosciences

In other Assembly Biosciences news, Director Michael Houghton purchased 3,202 shares of Assembly Biosciences stock in a transaction that occurred on Monday, December 30th. The stock was purchased at an average price of $15.61 per share, for a total transaction of $49,983.22. Following the transaction, the director now directly owns 3,202 shares in the company, valued at $49,983.22. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 5.10% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of ASMB. JPMorgan Chase & Co. grew its holdings in shares of Assembly Biosciences by 5,137.3% during the third quarter. JPMorgan Chase & Co. now owns 3,509 shares of the biopharmaceutical company's stock worth $53,000 after buying an additional 3,442 shares during the last quarter. Palumbo Wealth Management LLC purchased a new position in shares of Assembly Biosciences in the 4th quarter valued at approximately $180,000. Marshall Wace LLP grew its stake in shares of Assembly Biosciences by 16.5% in the 4th quarter. Marshall Wace LLP now owns 14,823 shares of the biopharmaceutical company's stock valued at $234,000 after purchasing an additional 2,098 shares during the last quarter. FMR LLC raised its stake in shares of Assembly Biosciences by 29.7% during the third quarter. FMR LLC now owns 15,855 shares of the biopharmaceutical company's stock worth $240,000 after purchasing an additional 3,635 shares during the last quarter. Finally, Man Group plc purchased a new position in Assembly Biosciences in the 4th quarter valued at $309,000. 19.92% of the stock is currently owned by institutional investors and hedge funds.

About Assembly Biosciences

Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.